國家衛生研究院 NHRI:Item 3990099045/10569
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 856670      Online Users : 806
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10569


    Title: Sitagliptin and oral cancer risk in type 2 diabetes patients
    Authors: Tseng, CH
    Contributors: National Institute of Environmental Health Sciences
    Abstract: The reimbursement database of the Taiwan's National Health Insurance was used to evaluate oral cancer risk after sitagliptin use. Patients newly diagnosed of type 2 diabetes during 1999-2008 were recruited. A 1:1 propensity score matched-pair sample of 39195 ever users and 39195 never users were followed up until December 31, 2011. Cox regression incorporated with the inverse probability of treatment weighting using propensity score was used to estimate hazard ratios. Results showed that the overall hazard ratio was not statistically significant (0.956, 95% confidence interval: 0.652-1.401). However, in tertile analyses, the hazard ratio for the first (< 7.47 months), second (7.47-15.63 months) and third (> 15.63 months) tertile of cumulative duration was 1.563 (0.963-2.537), 1.236 (0.738-2.071) and 0.345 (0.164-0.725), respectively; and was 1.575 (0.963-2.575), 1.224 (0.738-2.033) and 0.347 (0.165-0.731), respectively, for the first (< 19,600 mg), second (19,600-42,200 mg) and third (> 42,200 mg) tertile of cumulative dose. Sensitivity analyses after excluding patients who developed any other cancer during follow-up did not change the results substantially. Additionally, the risk of oral diseases that may predispose to oral cancer (i.e., "gingival and periodontal diseases" and/or "oral mucosal lesions") paralleled the risk pattern of oral cancer, suggesting a possible explanation for the risk change of oral cancer related to sitagliptin. In conclusion, sitagliptin may reduce oral cancer risk when the cumulative duration is > 15.63 months or the cumulative dose is > 42,200 mg.
    Date: 2017-11
    Relation: Oncotarget. 2017 Nov;8(57):96753-96760.
    Link to: http://dx.doi.org/10.18632/oncotarget.18239
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000419395000033
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85033776209
    Appears in Collections:[Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB28599318.pdf1182KbAdobe PDF173View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback